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Abstract
Introduction: Inefficient clearance of copious respiratory secretion is a cause of non-invasive positive pressure 
ventilation (NPPV) failure, especially in chronic respiratory patients with community-acquired-pneumonia (CAP) and 
impaired consciousness. We postulated that in such a clinical scenario, when intubation and conventional mechanical 
ventilation (CMV) are strongly recommended, the suction of secretions with fiberoptic bronchoscopy (FBO) may 
increase the chance of NPPV success. The objective of this pilot study was, firstly, to verify the safety and effectiveness 
of early FBO during NPPV and, secondly, to compare the hospital outcomes of this strategy versus a CMV-based 
strategy in patients with decompensated chronic obstructive pulmonary disease (COPD) due to CAP who are not 
appropriate candidates for NPPV because of inefficient mucous clearance and hypercapnic encephalopathy (HE).
Methods: This is a 12-month prospective matched case-control study performed in one respiratory semi-intensive 
care unit (RSICU) with expertise in NPPV and in one intensive care unit (ICU). Fifteen acutely decompensated COPD 
patients with copious secretion retention and HE due to CAP undergoing NPPV in RSICU, and 15 controls (matched for 
arterial blood gases, acute physiology and chronic health evaluation score III, Kelly-Matthay scale, pneumonia 
extension and severity) receiving CMV in the ICU were studied.
Results: Two hours of NPPV significantly improved arterial blood gases, Kelly and cough efficiency scores without FBO-
related complications. NPPV avoided intubation in 12/15 patients (80%). Improvement in arterial blood gases was 
similar in the two groups, except for a greater PaO2/fraction of inspired oxygen ratio with CMV. The rates of overall and 
septic complications, and of tracheostomy were lower in the NPPV group (20%, 20%, and 0%) versus the CMV group 
(80%, 60%, and 40%; P < 0.05). Hospital mortality, duration of hospitalisation and duration of ventilation were similar in 
the two groups.
Conclusions: In patients with decompensated COPD due to CAP who are candidates for CMV because of HE and 
inability to clear copious secretions, NPPV with early therapeutic FBO performed by an experienced team is a feasible, 
safe and effective alternative strategy.
Introduction
Non-invasive positive pressure ventilation (NPPV) is the
first-line treatment of hypercapnic acute respiratory fail-
ure (ARF) in severe chronic obstructive pulmonary dis-
ease (COPD) exacerbations. Compared with standard
medical therapy, it reduces the rate of endotracheal intu-
bation (ETI) and the associated complications, as well as
the mortality and length of stay in hospital [1,2]. How-
ever, the inefficacy to spontaneously clear airways from
an excessive burden of respiratory secretions is likely to
cause NPPV failure [3,4]. This is due to the kinds of inter-
faces used to deliver NPPV, which do not allow direct
access into the airways. Conversely, during conventional
mechanical ventilation (CMV) respiratory secretions may
be easily aspirated via the endotracheal tube.
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This is the reason why most randomised controls trials
(RCTs) of NPPV for ARF have excluded patients without
an efficient clearance of secretions. As a matter of fact,
the inability to spontaneously remove respiratory secre-
tions has been considered a relative contraindication to
start NPPV in ARF, especially if it occurs in patients with
impaired consciousness and depressed cough [1,2]. In
fact, the coexistence of abundant secretions and senso-
rium depression 'triggers' a vicious circle that leads to a
progressive clinical-physiological deterioration, which
eventually requires ETI.
Few published data suggested that some non-invasive
physiotherapeutic techniques may improve mucous
clearance in COPD exacerbations managed with NPPV
[ 5 - 7 ] .  H o w e v e r ,  t o  o u r  k n o w l e d g e ,  n o  s p e c i f i c  s t u d i e s
have addressed the feasibility and usefulness of any avail-
able mucous clearance strategies in patients who are not
eligible for NPPV because of their incapability to sponta-
neously eliminate accumulated secretions associated with
hypercapnic encephalopathy (HE).
Recent studies have shown that, within expert units,
NPPV is feasible and may be applied with success in
moderate-to-severe HE due to COPD exacerbations with
a similar short- and long-term survival but fewer septic
complications compared with CMV [8-10]. Moreover,
despite the uncertain role of NPPV to successfully treat
severe community-acquired pneumonia (CAP) in de novo
hypoxaemic ARF patients [1,2], one RCT demonstrated
the effectiveness of NPPV in reducing the rate of ETI in
hypercapnic COPD exacerbations precipitated by CAP
[11]. Furthermore, accumulated evidence supports the
feasibility and safety of performing a diagnostic fiberoptic
bronchoscopy (FBO) with broncho-alveolar lavage (BAL)
for a suspected pneumonia under the assistance of NPPV
in patients with either pure hypoxaemic or hypercapnic
ARF [12-17].
We postulated that in the clinical scenario of patients
with COPD decompensations secondary to CAP who
require ETI and ventilatory assistance because of
impaired mucous clearance and HE, the early suction of
secretions with FBO performed during NPPV by an
expert team is feasible. It may also allow for the successful
expanded application of NPPV. The choice of including
episodes of CAP in place of simple exacerbations of
COPD was based on the intention of 'stressing' the model
of bronchial hypersecretion to test the feasibility of this
new FBO-NPPV approach.
We therefore performed this pilot study with the aims,
firstly, to verify the safety and effectiveness of early thera-
peutic FBO to clear airways during NPPV and, secondly,
to compare the hospital outcomes of this strategy admin-
istered in a respiratory semi-intensive care unit (RSICU)
with the CMV-based strategy provided in the ICU to
treat ARF episodes occurring in COPD patients who
were not appropriate candidates for NPPV because of
their inability to remove copious secretion and HE due to
CAP-triggered decompensations.
Materials and methods
Study design
This prospective case-control study was performed
between January and December 2008 in two centres: a
three-bed RSICU in the Respiratory Division and the
eight-bed general ICU of S. Donato Hospital, Arezzo,
Italy. The study protocol was approved by the ethics com-
mittee and by the institutional review board and was per-
formed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki. Due to the
depressed mental status of the patients, the informed
written consent was obtained from their next of kin. The
decision-making attending physicians of both centres
were not aware of their participation in the study because
the strategy was based on early FBO during both NPPV
and CMV in ARF patients with impaired mucous clear-
ance, which had been part of their clinical practice for
several years.
Cases (NPPV group)
All consecutive COPD patients [18] with ARF precipi-
tated by severe CAP [19], showing depressed sensorium
and bronchial hypersecretion, admitted to the RSICU
over the observed period were considered eligible for the
study. Diagnosis of CAP was radiographically confirmed
in all cases while its severity was ascertained according to
the presence of at least three criteria recommended by
the Infective Diseases Society of America (IDSA) and the
American Thoracic Society (ATS) guidelines [19]. To be
included in the study, the patients had to meet all the fol-
lowing criteria while breathing oxygen via a venturi mask:
(a) pH less than 7.33 and partial pressure of arterial car-
bon dioxide (PaCO2) above 55 mmHg; (b) partial pres-
sure of arterial oxygen (PaO2)/fraction of inspired oxygen
(FiO2) ratio less than 250; (c) dyspnoea at rest with respi-
ratory rate (RR) above 25 breaths/min; (d) use of acces-
sory respiratory muscles or paradoxical abdominal
breathing; (e) HE as assessed by the Kelly-Matthay score
between two and four [20]; (f) inability to spontaneously
clear airways from excessive secretions, as expressed by
the lowest score of an arbitrary cough efficiency scale
evaluated by the nurses on the basis of the volume of the
expelled sputum after three hard coughing efforts (1 =
less than 2 ml; 2 = between 2 and 6 ml and; 3 = more than
6 ml) [21]. Due to the poor patient's cooperation, more
objective tools for the assessment of cough strength (i.e.
peak expiratory cough flow) were not applied.
It should be noted that before the implementation of
the FBO-NPPV protocol in the RSICU clinical practice all
the potential eligible cases had been intubated and trans-Scala et al. Critical Care 2010, 14:R80
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ferred to the ICU due to the high likelihood of NPPV fail-
ure associated with depressed cough and sensorium [1,2].
Exclusion criteria from the FBO-NPPV protocol were:
(a) refusal of NPPV; (b) facial deformity sufficient to pre-
clude mask fitting; (c) preexisting psychiatric and/or neu-
rological disorders unrelated to HE; (d) upper
gastrointestinal bleeding; (e) upper airway obstruction;
(f) acute coronary syndromes; (g) tracheostomy or ETI
before admission; (h) need for urgent ETI due to cardiac
or respiratory arrest or psychomotor agitation, severe
haemodynamic instability [10]. The two major criteria
recently suggested by IDSA/A TS guidelines [19] for the
ICU admission of patients with severe CAP (i.e. manda-
tory CMV due to the reasons detailed in point h of the
guidelines and septic shock with need for vasopressors)
were also considered reasons of exclusion from the FBO-
NPPV protocol.
Before FBO
NPPV (V ela, Viasys, Loma Linda, CA, USA) was deliv-
ered in pressure support (PS) mode with positive end-
expiratory pressure (PEEP) via a well-fitting full-face
mask (Mirage, ResMed, San Diego, CA, USA) with the
addition of a heated humidifier (DAR HC 2000, Mallinck-
rodt DAR, Mirandola, Italy). PS was initially set at 10
cmH2O and then titrated to achieve an expiratory tidal
volume of 8 to 10 ml/kg and a RR below 25 breaths/min
to a maximum of 25 cmH2O depending on clinical and
arterial blood gases (ABGs) response and patient toler-
ance. PEEP was always set at 5 cmH2O [10]. Back-up RR
was set at a 14 to 18 breaths/min, lower than the patient's
spontaneous RR. FiO2 was initially set at 0.70.
During FBO
FBO was performed after the patients had adapted to
NPPV. A T-adapter was attached to the face mask for the
insertion of FBO (model P40; Olympus; Tokyo, Japan) via
a nasal route [14] (Figure 1). During the bronchoscopic
procedure, the FiO2 was kept at 1.0. Topical anaesthesia
of the nasopharynx (10% lidocaine spray solution) and
larynx (2% lidocaine hydrochloride, not exceeding an
overall does of 200 mg) was performed before advancing
the bronchoscope into the tracheobronchial tree [14]. No
pharmacological sedation and/or analgesia was adminis-
tered during the FBO-NPPV procedure. Firstly, a careful
suction of bronchial secretions was performed to fully
clear airways. Then, the tip of the FBO was wedged into
the bronchial subsegment, which was tributary of the
lung consolidation showed by the chest radiograph. BAL
was performed by sequential instillation of five aliquots
of 30 mL non-bacteriostatic saline solution at room tem-
perature. The retrieved fluid was sent immediately to the
microbiology laboratory for microscopic analysis and cul-
turing. The isolated bacteria with a count of 104 cfu/mL
or more of the BAL fluid were considered as the aetiolog-
ical agents of CAP [22].
After FBO
After the bronchoscopic procedures, the FiO2  was
decreased in order to maintain the pulse oximetry (SpO2)
at 90 to 94% and PS levels were adjusted according to the
criteria described in the pre-FBO phase.
NPPV was provided by nurses and physicians ade-
quately trained with 12 years of accumulated experience
with this technique in the RSICU following yearly courses
aiming to educate naïve units, update on newly intro-
duced equipment, and share internal protocols. The
mean nurse:patient ratio in the overall respiratory divi-
sion was 1:6, with one nurse for each shift dedicated to
the RSICU [10]. Routine chest physiotherapy was avail-
able to facilitate expectoration. Electrocardiogram, SpO2,
and noninvasive blood pressure were monitored continu-
ously. ABGs were sampled as follows: at baseline; before,
during, and at the end of FBO (i.e. after two hours of
NPPV); after four hours of NPPV; and subsequently as
clinically indicated. Prompt ETI with transfer to the ICU
was available at any time during NPPV treatment.
NPPV was applied continuously at least during the first
12 to 24 hours. Once clinical status, Kelly-Matthay score,
and ABGs improved, NPPV was administered intermit-
tently with sessions lasting two to six hours three times
daily [10]. Then PS was reduced progressively twice a day
by 3 cmH2O until a level of 8 cmH2O or less was reached.
NPPV weaning was considered successful after three days
of ventilation or more when all the following criteria were
met for longer than 24 hours while on breathing with
oxygen (FiO2 0.28): pH above 7.35, SpO2 above 90%, RR
less than 30 breaths/min, Kelly-Matthay score 1, cough
score 3, radiographic improvement of CAP, and stable
haemodynamic status [10].
NPPV was considered to have failed if at least one of
the following criteria for ETI was met: cardiac arrest or
severe haemodynamic instability; respiratory arrest or
gasping; mask intolerance; lack of improvement in cough
score; and/or worsening of ABGs or of sensorium level
during NPPV [10]. Tracheostomy was performed in intu-
bated patients after NPPV failure when the weaning pro-
cess was prolonged for more than 12 days. Patients who
failed with NPPV were promptly intubated in the RSICU
but they had to be moved to the general ICU because the
low monitoring level and nurse-to-patient ratio available
in the respiratory unit could not allow the safely manage-
ment of invasively ventilated patients.
Medical therapy
All patients received standard medical therapy consisting
of: controlled oxygen therapy during NPPV-free periods;
salbutamol and anticholinergic drugs during NPPV via a
spacer; intravenous aminophylline and corticosteroids;Scala et al. Critical Care 2010, 14:R80
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subcutaneous low-molecular weight heparin; and therapy
for comorbidities if necessary. Antibiotic strategy was
based on empirical intravenous administration of levo-
floxacin plus β-lactam (for penicillin-allergic patients:
levofloxacin plus aztreonam), unless some risk factors for
Pseudomonas aeruginosa were identified (ciprofloxacin
plus anti-pseudomonal β-lactam) [19]. Antibiotic-ther-
apy was later eventually adjusted to the results of bacte-
rial cultures and antibiogram according to a de-escalation
strategy and/or a drug resistance.
Controls (CMV group)
Controls were selected from all COPD patients consecu-
tively admitted to the ICU during the same period who
received CMV according to the same inclusion criteria
used for the NPPV group, and whose data were prospec-
tively collected. Specifically, the nurses who worked in
the ICU applied the same assessment scores, cough effi-
ciency included, used in the RSICU. CMV patients show-
ing any of the NPPV group exclusion criteria except for
refusal of NPPV or facial deformity sufficient to preclude
mask fitting were not included in the study to prevent a
potential bias of selection [10]: inclusion in previous
studies, major criteria of ICU admission for severe CAP
[19] and ETI after the failure of an initial NPPV trial were
considered further reasons for exclusion. The matching
of controls was performed manually according to the fol-
lowing criteria: PaO2/FiO2 (± 10), PaCO2 (± 5 mmHg), pH
(± 0.03), Kelly-Matthay score (± 0), the severity and the
extension of CAP according to the CURB-65 (confusion,
urea, respiratory rate, blood pressure, age 65 or over)
score [19] and the number of lobes radiographically
involved (± 0) before mechanical ventilation (MV),
respectively; acute physiology and chronic health evalua-
tion (APACHE) score III [23] (± 5 points) assessed within
the first 24 hours after admission. When more than one
potential control was present, the best matched subject
was selected.
The standard therapy protocol was the same as that
described for the NPPV group [10] except that controls
were sedated at the time of intubation (2 mg/kg propofol
intravenously followed by a continuous infusion at 0.5 to
3 mg/kg per hour usually lasting for 24 to 36 hours); no
paralysing drugs were used. The ICU nurse:patient ratio
was 1:2. CMV was delivered via an ICU ventilator (Sie-
mens 300, Siemens, Berlin, Germany, or Puritan Bennett
840, Covidien, Dublin, Ireland) in assist-control mode
(tidal volume 8 to 10 ml/kg; back-up RR 10 to 14 breaths/
min; FiO2 0.70; PEEP 5 cmH2O). In addition to the usual
nursing addressed to the suction of secretions through
the endotracheal tube and to the routinely applied chest
physiotherapy, FBO with BAL was performed in the
CMV group within one hour after ETI following the same
Figure 1 Fiberoptic bronchoscopy. (a) The fiberoptic bronchoscopy (FBO)-noninvasive positive pressure ventilation (NPPV) procedure. (b) The 
trans-nasally introduction of the bronchoscope. F = fiberoptic bronchoscope; H = heated humidifier; M = mask; T = T-adapter; V = ventilator.
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procedure and adjustment of FiO2 used in the NPPV
group. When spontaneous breathing reappeared (usually
≥ 24 hours), the ventilator mode was switched to PS [24],
following the same criteria used for the NPPV group.
Extubation was performed if the patient was able to toler-
ate a one to two hour T-piece trial with FiO2 0.28 (pH >
7.35, SpO2 > 90%, RR < 30 breaths/min, normal senso-
rium, efficient cough, radiographic CAP improvement,
stable haemodynamic status). If after 12 days the patient
was still intubated and ventilated, tracheostomy was per-
formed according to the judgement of the physician in
charge; then weaning was resumed following the above
protocol.
Data collection and end-points
In addition to the matching variables, other parameters
were collected: age, gender, body mass index, spirometry
and ABGs in a stable status within the previous six
months, number of exacerbations experienced in the pre-
vious year, comorbidities as assessed by the Charlson
score [25], do not resuscitate (DNR) order, antibiotic use
in the previous three months, RR, heart rate, hospital stay
before MV. Urinary antigens for Legionella and Strepto-
coccus pneumoniae, and blood cultures were also per-
formed.
The primary endpoints were: 1) the safety (need for
urgent ETI) and effectiveness (changes in ABGs, Kelly-
Matthay and cough scores) of FBO within two hours of
NPPV; 2) the rate of major complications [24], especially
septic complications and nosocomial pneumonia
(included pulmonary aspiration) which were diagnosed
using strict criteria [26,27]. Assuming a power of 80%
with an α-error of 0.05, a sample size of 31 patients was
calculated on the basis of the reported finding of major
complications in NPPV compared with CMV-treated
ARF patients with HE (30% vs. 65%) [10].
Secondary endpoints were: microbiological findings of
BAL and relative adjustments of empiric antibiotic ther-
apy, ABG changes, in-hospital mortality, tracheostomy,
and length of hospital stay and MV.
Statistical analysis
The Kolmogorov-Smirnov test was used to verify
whether all recorded variables were normally distributed
(P > 0.05). Continuous data are expressed as mean (stan-
dard deviation) if distributed normally or as median
(interquartile range) if not; categorical data are presented
as frequency. Continuous variables were compared with
the two-tailed unpaired Student's t test (parametric data)
or the Mann-Whitney U test (nonparametric data). Cate-
gorical data were compared using the chi-squared or,
when appropriate, Fisher's exact test. A P value less than
0.05 was considered statistically significant. Analyses
were performed using version 10.0 of SPSS software
(SPSS, Chicago IL, USA).
Results
During the study period, 38 and 33 eligible consecutive
patients with acute decompensation of COPD triggered
by CAP, showing depressed sensorium and bronchial
hypersecretion, were admitted to the RSICU for NPPV
and to the ICU for CMV, respectively. After careful
matching (100% for all pre-defined parameters), 15
patients from each group were selected (Table 1); cases
and controls did not differ significantly on any the vari-
ables used for matching. Concerning non-matching crite-
ria, the two groups were similar except for age and
Charlson score, which were significantly greater in the
NPPV and CMV groups (Table 2).
Table 1: Matching criteria at baseline between the non-invasive positive pressure ventilation (NPPV) and the conventional 
mechanical ventilation (CMV) groups
NPPV (n = 15) CMV (n = 15) P
pH, mean (SD) 7.27 (0.02) 7.27 (0.03) 0.858
PaO2/FiO2, mean (SD) 163 (60) 165 (13) 0.910
PaCO2 mmHg, mean (SD) 76 (7) 78 (13) 0.596
APACHE III score, mean (SD) 71 (9) 73 (6) 0.396
Kelly-Matthay score, mean (SD) 3.4 (1.2) 3.2 (1.0) 0.633
CAP, n involved lobes, median (IQR) 2 (1-2) 1 (1-2) 0.486
CURB-65 score, median (IQR) 3 (2-4) 3 (2-3) 0.806
APACHE, acute physiology and chronic health evaluation; CAP, community-acquired pneumonia; CURB-65, confusion, urea, respiratory rate, 
blood pressure, age 65 or over; FiO2, fraction of inspired oxygen; IQR, interquartile range; PaCO2, partial pressure of arterial carbon dioxide; 
PaO2, partial pressure of arterial oxygen; SD, standard deviation.Scala et al. Critical Care 2010, 14:R80
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The clinical physiological features of the 15 recruited
cases did not differ from those of the 23 patients who
were admitted to the RSICU and treated with NPPV but
were not selected after the matching process (Table 3):
this homogeneity excluded a bias due to lack of internal
validity of the sample.
FBO was performed 18.5 (6.9) minutes after starting
NPPV and lasted 7.8 (3.1) minutes with the removal of 23
(18) ml of respiratory secretions. No major complica-
tions, including the need for emergent ETI and pneu-
mothorax, occurred before, during, or after FBO within
two hours of NPPV. All patients tolerated FBO well while
on NPPV. PaO2/FiO2 and SpO2 significantly increased
before, during and after FBO compared with baseline,
while the improvement in PaCO2 and pH became statisti-
cally significant after FBO in the NPPV group (Table 4).
Both Kelly-Matthay and cough efficiency scores signifi-
cantly improved after two hours of NPPV (Figure 2). Eval-
uation of sensorium and cough was not possible in the
CMV group for the administration of sedation.
BAL allowed the bacterial diagnosis of pneumonia in
80% of patients in the NPPV group and 60% of patients in
the CMV group. The pattern of the isolated microorgan-
isms was similar in the two groups. As a result of the BAL
findings, the empiric antibiotic therapy was changed in
33.3% and 26.7% of NPPV and CMV-treated patients,
respectively, (P > 0.05) due to de-escalation therapy (3 in
the NPPV group and 2 in the CMV group) and multi-
drug resistance of S. pneumoniae (1 in the NPPV group
and 1 in the CMV group) and P. aeruginosa (1 in the
NPPV group and 1 in the CMV group) (Table 5). Urinary
pneumococcal antigen was positive in seven patients (4 in
the NPPV group and 3 in the CMV group), while urinary
antigen for Legionella was never identified. Blood cul-
tures were only positive in three patients with pneumo-
coccal pneumonia (1 in the NPPV group and 2 in the
CMV group).
Compared with baseline, pH and PaCO2 had improved
similarly in the NPPV and CMV groups after two hours
and at the end of MV. Conversely, PaO2/FiO2 level was
significantly greater in the CMV group than in the NPPV
group both after two hours and at the end of MV (Figure
3). Mean values of PS were similar after two hours (NPPV
group: 18.2 (4.5) cmH2O; CMV group: 19.0 (5.6) cmH2O)
and at the end of MV (NPPV group: 16.8 (7.9) cmH2O;
CMV group: 17.3 (8.1) cmH2O).
Table 2: Characteristics of the noninvasive positive pressure ventilation (NPPV) and the conventional mechanical 
ventilation (CMV) groups according to nonmatching criteria
NPPV (n = 15) CMV (n = 15) P
Age, years, mean (SD) 80 (5) 73 (5) 0.001
Male, n (%) 12 (80) 9 (60) 0.427
BMI, Kg/m2, mean (SD) 25 (4) 26 (3) 0.509
FEV1, % of pred., mean (SD)a 30 (5) 31 (5) 0.866
FVC, % of pred., mean (SD)a 39 (8) 42 (8) 0.262
PaO2, mmHg, mean (SD)a 51 (3) 54 (3) 0.105
PaCO2, mmHg, mean (SD)a 59 (5) 57 (4) 0.257
pH, mean (SD)a 7.39 (0.02) 7.40 (0.03) 0.514
Charlson score, median (IQR) 2 (1-2) 1 (1-1) 0.041
Exacerbations, median (IQR)b 1.7 (0.9) 1.1 (1.0) 0.600
Antibiotic use, n (%)c 5 (33.3) 6 (40.0) 0.705
DNR order, n (%) 2 (13.3) 0 (0.0) 0.483
Pre-MV hospital, days median 
(IQR)
1 (1-2) 1 (1-2) 0.646
RR, bpm, mean (SD) 34 (4) 36 (3) 0.160
HR, bpm, mean (SD) 102 (12) 108 (12) 0.224
PS, cmH2O, mean (SD) 18 (4) 17 (4) 0.445
BMI, body mass index; DNR, do-not-resuscitate; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; HR, heart rate; 
IQR, interquartile range MV, mechanical ventilation; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial 
oxygen; PS, pressure support; RR, respiratory rate; SD, standard deviation.
a stable status within the previous 6 months.
b within the previous 12 months.
c within the previous 3 months.Scala et al. Critical Care 2010, 14:R80
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The complication rate was significantly higher in the
CMV than in the NPPV group due to a greater occur-
rence of infectious events. Pulmonary aspiration did not
occur in the NPPV group. Tracheostomies were signifi-
cantly fewer in the NPPV than in the CMV group. Hospi-
tal mortality, and length of hospitalisation and MV were
similar in the two groups (Table 6).
NPPV failed in 3 of 15 patients (20%) after 17.3 (9.5)
days and a total of 216.0 (109.3) hours of ventilation due
to worsening ABGs (n = 2) and secretion retention (n =
1). All of them developed septic complications after ETI
and died due to septic shock (n = 2) or cardiac arrest (n =
1). Mild facial skin erythema occurred in four patients.
Causes of in-hospital death in the CMV group were
septic shock (n = 5), acute renal failure (n = 1), cardiac
arrest (n = 1), and after tracheostomy (n = 3).
Discussion
This is the first study to verify the safety and effectiveness
of the early therapeutic FBO during NPPV. It also com-
pared the outcomes of this strategy with ETI and CMV in
COPD decompensations for CAP in patients who were
not considered appropriate candidates for NPPV because
of HE and an inability to spontaneously eliminate an
excessive burden of secretions. Two hours of NPPV asso-
ciated with FBO-based mucous clearance significantly
improved ABGs, sensorium and cough efficiency without
any complications. Improvement in PaCO2 and pH, as
well as hospital mortality, and durations of hospitalisation
a n d  M V  w e r e  s i m i l a r  i n  t h e  N P P V  a n d  C M V  g r o u p s.
Interestingly, NPPV significantly reduced serious infec-
tious complications compared with CMV.
The main limitation of the present study is the case-
control design and lack of randomisation, which may bias
results in favour of the treatment under investigation.
Both cases and controls were prospectively enrolled dur-
ing the same period, but unfortunately we could not per-
form a RCT because CMV could be applied only in the
ICU, and the unpredictability of bed availability in differ-
ent units made randomisation difficult. Furthermore,
even if available in both units, NPPV was mainly applied
in the RSICU to treat exacerbations of chronic respira-
tory disorders for cost-utility advantages [28]; conversely,
in ICU there was a large priority to admit complex and
severe  de novo acute diseases requiring both invasive
monitoring and CMV (i.e. post-surgery ARF, multi-organ
failures, poly-traumas etc.). On the other hand, well-
designed observational studies may yield reliable results
when cases and controls are well balanced by careful
matching, and the interference of confounding factors is
minimised [29]. In our study, cases were similar to con-
trols not only for the matching criteria (ABGs, APACHE
III score, sensorium and severity of CAP) but also for
other historical clinical physiological features. Con-
versely, the older age and more numerous comorbidities
of the NPPV group could have favoured the CMV treat-
ment. Moreover, the clinical physiological homogeneity
between the cases and NPPV patients who were not
recruited after the matching process excluded a bias of
selection.
Another concern regarding the study design is the dif-
ferent setting where the two groups were treated. How-
ever, the lower intensity of care in the RSICU compared
with the ICU (e.g., nurse:patient ratio) could have con-
Table 3: Characteristics of patients receiving noninvasive positive pressure ventilation (NPPV) according if they were or 
were not recruited in the study
Recruited (n = 15) Non-recruited (n = 23) P
Age, years, mean (SD) 80 (5) 79 (4) 0.803
Male, n (%) 12 (80) 14 (61) 0.294
BMI, Kg/m2, mean (SD) 25 (4) 25 (3) 0.537
Charlson score, median (IQR) 2 (1-2) 2 (1-1) 0,535
pH, mean (SD) 7.27 (0.02) 7.28 (0.01) 0.677
PaO2/FiO2, mean (SD) 163 (60) 169 (15) 0.988
PaCO2 mmHg, mean (SD) 76 (7) 75 (10) 0.647
APACHE III score, mean (SD) 71 (9) 70 (6) 0.804
Kelly-Matthay score, mean 
(SD)
3.4 (1.2) 3.2 (1.0) 0.633
CAP, n involved lobes, median 
(IQR)
2 (1-2) 1 (1-2) 0.883
APACHE, acute physiology and chronic health evaluation; BMI, body mass index;
CAP, community-acquired pneumonia; FiO2, fraction of inspired oxygen; IQR, interquartile range; PaCO2, partial pressure of arterial carbon 
dioxide; PaO2, partial pressure of arterial oxygen; SD, standard deviation.Scala et al. Critical Care 2010, 14:R80
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tributed to a higher rate of NPPV failures. Moreover, the
application of the same inclusion and exclusion criteria as
well as the same standard therapies and nursing activities
(i.e. cough and sensorium assessment) in the two units
belonging to the same hospital should have minimised
this bias. Another point is the implementation of shared
intra-hospital multi-disciplinary protocols for the man-
agement of severe COPD exacerbations. It should also be
emphasised that our RSICU has acquired a high level of
expertise with NPPV and FBO techniques, including for
patients with HE [9,10], with the capability of promptly
intubating failing patients. Thus our findings may not be
reproducible in units less experienced in NPPV.
Finally, a criticism may be also directed to the choice of
CMV-treated patients as a control group. It could be
argued that a comparison between NPPV plus FBO vs
NPPV alone may have been a more appropriate design to
address the clinical outcomes of the study. This would be
true for COPD patients in an earlier phase of their exac-
erbation compared with those of our study who were not
clearly eligible for NPPV for their severe sensorium and
cough depression [1,2]. The risk connected with a
delayed intubation would not have been justified in
selected COPD patients with a high chance of NPPV fail-
ure. However, a trial comparing NPPV combined or not
w i t h  F B O  i n  l e s s  s e v e r e  C O P D  d e c o m p e n s a t i o n s  w i t h
impaired mucous clearance could be of help to integrate
the findings to the present study.
Due to the lack of direct access to the airways, NPPV is
not appropriate when patients are incapable of spontane-
ously removing abundant secretions. A rate of NPPV fail-
ure of 61% was reported in 23 patients with ARF of
different aetiology showing copious secretions [4]. More-
over, in two series of COPD exacerbations with moder-
ate-to-severe HE [9,10], the inefficient clearance of
secretions caused 33% and 43% of all NPPV failures,
respectively. Interestingly, Conti and colleagues [24]
showed that in two of the nine COPD patients who
required ETI within two to six hours of ventilation, NPPV
failed for the difficult management of copious secretions.
As a matter of fact, the possibility of clearing the airways
in the early phases of NPPV is likely to reduce the need
for ETI in patients with an unfavourable balance between
an excessive burden of secretions (e.g. COPD exacerba-
tions due to CAP) and an inefficient spontaneous clear-
ance (e.g. poor cough reflex due to HE).
The most innovative finding of our study is the success-
ful application for the first time of early FBO as a mucous
clearance technique under NPPV in patients with COPD
exacerbations who should have been intubated for their
inability to cope with copious secretions and their altered
level of consciousness [1,2]. This is particularly true for
CAP-triggered COPD decompensations, which represent
a 'challenging' model in terms of the burden of secretions
also involving the distal airways. With this strategy, FBO-
based suction of accumulated secretions during ventila-
tion facilitated NPPV to improve ABGs, sensorium level
and cough efficiency. The quick favourable effect of such
a therapeutic approach is not surprising because it acts by
interrupting the vicious circle triggered by the coexis-
tence of abundant secretions and sensorium depression.
However, the application of the common therapist
manoeuvres to manage secretions in critical respiratory
patients was essential for the success of the FBO-NPPV
strategy in our RSICU [30]. This may explain why we did
not need to repeat the FBO procedure for the recurrence
of mucous accumulation in all but one case who failed
NPPV after 10 days of ventilation.
Figure 2 (a) Changes of Kelly--Matthay and (b) cough efficiency 
score after two hours of noninvasive ventilation (NPPV). Values are 
expressed as mean (standard deviation). * P < 0.005 vs. baseline.
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*Scala et al. Critical Care 2010, 14:R80
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The lack of major complications is consistent with pre-
vious reports, which clearly demonstrated the feasibility
and safety of FBO plus BAL performed under the assis-
tance of NPPV in patients with severe hypoxaemic and
hypercapnic ARF who should have to be otherwise intu-
bated to allow such invasive procedures [12-17]. There-
fore, it should be underlined, as the novelty of our study,
the safe use of FBO in patients with severe ARF requiring
a mandatory ventilatory support because no relevant
complications (cardiovascular, pneumothorax, emergent
intubation) were reported. In contrast, in previous stud-
ies [12-17] NPPV was applied with the aim to prevent
ABGs deterioration and the need for ETI during the BAL
performed in spontaneously breathing patients.
Although few articles have reported the efficacy of non-
invasive techniques in augmenting sputum production in
exacerbated alert COPD patients [5-7], these options may
not have been successful in patients with severe COPD
exacerbations with depressed sensorium and inefficient
cough.
In agreement with previous experiences, our study con-
firms the high success rate of NPPV when applied in
patients with hypercapnic ARF and reduced levels of con-
sciousness [8-10]. The finding of a relatively low rate of
ETI in our study parallels the results of a previous RCT,
which highlighted the different outcomes of NPPV in
CAP as a cause of ARF, depending on if ventilation was
delivered to COPD or non-COPD patients [11].
Table 4: Time course of arterial blood gases before, during and after fiberoptic bronchoscopy (FBO) in the noninvasive 
positive pressure ventilation (NPPV) group
pre-NPPV pre-FBO during FBO post-FBOa
pH, mean (SD) 7.27 (0.02) 7.29 (0.02) 7.29 (0.02) 7.37 (0.04)**
PaCO2 mmHg, mean 
(SD)
76 (7) 75 (8) 73 (7) 60 (3)**
PaO2/FiO2, mean (SD) 163 (60) 211 (39)** 203 (40)* 200 (70)**
SpO2, %, mean (SD) 79 (9) 93 (2)** 92 (3)** 92 (2)**
FiO2, mean (SD) 0.45 (10) 0.70 1.0 0.39 (12)
a after 2 hours of NPPV.
* P < 0.05 vs pre-NPPV.
** P < 0.05 vs pre-NPPV.
FiO2, fraction of inspired oxygen; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; SD, standard 
deviation; SpO2, pulse oximetry.
Table 5: Microbiological broncho-alveolar lavage (BAL) findings in the noninvasive (NPPV) and the conventional 
mechanical ventilation (CMV) groups
NPPV (n = 15)a CMV (n = 15)b P
Diagnostic yield (>104 cfu/ml), 
n (%)
12 (80.0) 9 (60.0) 0.427
Change in antibiotic-therapy, 
n (%)
5 (33.3) 4 (26.7) 1.000
Streptococcus pneumoniae, n 
(%)
5 (33.3) 4 (26.7) 1.000
Pseudomonas aeruginosa, n 
(%)
4 (26.7) 3 (20.0) 1.000
Staphylococcus aureus, n (%) 2 (13.3) 1 (6.7) 1.000
Haemophilus influenzae, n (%) 2 (13.3) 2 (13.3) 1.000
Enterobacteriaceae, n (%) 1 (6.7)c 1 (6.7)d 1.000
Moraxella catarrhalis, n (%) 1 (6.7) 0 (0) 1.000
a In three cases two microorganisms were isolated.
b In two cases two microorganisms were isolated.
cEscherichia coli.
dKlebsiella pneumoniae.Scala et al. Critical Care 2010, 14:R80
http://ccforum.com/content/14/2/R80
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The quick improvement of the sensorium level and of
the cough reflex together with the avoidance of ETI and
the less aggressive monitoring associated with NPPV
management in RSICU may have contributed to the
lower occurrence of septic nosocomial complications in
the NPPV group than in the CMV group. This is not
unexpected as the effectiveness of NPPV in preventing
ETI-correlated complications (i.e. nosocomial pneumo-
nia and VAP), especially in patients with chronic respira-
tory disorders, has been clearly demonstrated [31].
Furthermore, it could be speculated that the different
occurrence of nosocomial infections in the two groups
may at least in part justify the finding of fewer trachesto-
m ies  i n t he  NPPV  vs  t he  CM V gr o up;  t his  h ypot hes is
seems to be suggested by the trend towards a longer
duration of MV in patients who developed septic compli-
cations compared with these who did not (20 (6 to 28) vs
7 (5 to 12) days; P = 0.267). However, this data should be
interpreted with caution as the study was not powered for
assessing the differences in the rate of tracheostomy
between the groups.
The high diagnostic yield of BAL for the identification
of the bacterial aetiology of CAP both in NPPV (80%) and
in CMV-treated patients (60%) is difficult to compare
with previously published data (36 to 78%) [32-34] due to
the large heterogeneity existing among the different stud-
ies in terms of severity of CAP, underlying diseases, need
for MV, previous use of antibiotics, and hospital setting.
We decided to perform BAL to have more chances to
achieve a microbial diagnosis as an adequate sputum
sample was not easily available in such critical patients.
The spectrum of microorganisms isolated in our study
belongs to the typical bacterial pattern of CAP found in
patients with COPD at advanced stages [35,36]. Concern-
ing the change of the initial empirical antibiotic therapy
on the basis of BAL results, the rate of 26.7% and 33.3%
found in the CMV and NPPV groups, respectively, is con-
sistent with a recent finding of 27.3% reported in immu-
nocompetent CAP patients [32]. However, the clinical
meaning of this result should be scaled down if we con-
sider that the changes of the initial therapy were not due
to the inadequacy of the empiric approach recommended
b y  t h e  g u i d e l i n e s  f o r  s u c h  C O P D  p a t i e n t s  w i t h  s e v e r e
CAP [19] but to the de-escalation strategy and occur-
rence of drug resistance.
Some caveats are worth considering when interpreting
our results. Patients with HE and mucous accumulation
due to severe COPD exacerbations are critically ill and
warrant close observation in a skilled unit with the means
to promptly intubate the patient if necessary. Thus the
application of NPPV to treat severe ARF with the con-
c o m i t a n t  u s e  o f  F B O  t o  r e m o v e  a b u n d a n t  s e c r e t i o n s
should be reserved for centers where all staff members
have acquired sufficient experience with these kinds of
patients and these kinds of procedures [37].
Conclusions
In this pilot study we have shown that in acute COPD
decompensations due to CAP in patients who are not
considered appropriately eligible for a noninvasive venti-
latory approach because of HE and an inability to sponta-
neously clear copious secretions, NPPV with early FBO
performed by an experienced team is feasible, safe and
Figure 3 Trend of mean values of arterial blood gases. Values 
shown for before (pre-MV), after two hours (2 h-MV) and at the end of 
mechanical ventilation (end-MV) in the noninvasive positive pressure 
ventilation (NPPV) (Rectangles; pre-MV: n.15; 2 h-MV: n.15; end-MV: 
n.11) and the conventional mechanical ventilation (CMV) group (cir-
cles; pre-MV: n.15; 2 h-MV: n.15; end-MV: n.8). Dashed lines depicted 
the individuals values of pH, partial pressure of arterial oxygen (PaO2)/
fraction of inspired oxygen (FiO2), partial pressure of arterial carbon di-
oxide (PaCO2) of NPPV-treated patients. * P < 0.05 between the groups.Scala et al. Critical Care 2010, 14:R80
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effective. Importantly, this innovative strategy was not
associated with relevant complications, such as emergent
intubation, cardiovascular events and pneumothorax.
Moreover, compared with CMV, this new approach
reduces nosocomial infections associated with ETI. Even
if this NPPV strategy may be a successful alternative to
CMV to manage selected COPD patients within expert
units with prompt access to ETI, larger RCTs are neces-
sary to confirm this preliminary result and, therefore, to
test the efficacy of the FBO-NPPV protocol in a single
center applied to an earlier time-course of COPD decom-
pensations when ETI is not mandatory.
Key messages
• NPPV with early FBO performed by an experienced
team is a potential alternative to ETI in acute COPD
decompensations with HE and inability to clear copi-
ous secretions.
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